Steve Edelman, MD

home / authors / steve-edelman-md

Articles

Bridging the Gap for T1D Management

Steve Edelman, MD;Linda A. DiMeglio, MD;Egils K. Bogdanovics, MD;Justin M. Gregory, MD, MSC;Schafer Boeder, MD

August 30th 2023

Expert endocrinologists provide final thoughts on addressing unmet needs and improving the management of T1D.

Investigational Approaches for Treating T1D

Steve Edelman, MD;Linda A. DiMeglio, MD;Egils K. Bogdanovics, MD;Justin M. Gregory, MD, MSC;Schafer Boeder, MD

August 30th 2023

Schafer Boeder, MD, and Egils K. Bogdanovics, MD, share approaches to prevention, preservation, and replacement therapies for the treatment of T1D.

Improving Access to Teplizumab and Future Treatments of T1D

Steve Edelman, MD;Linda A. DiMeglio, MD;Egils K. Bogdanovics, MD;Justin M. Gregory, MD, MSC;Schafer Boeder, MD

August 23rd 2023

Experts in endocrinology share challenges of patient access to type 1 diabetes treatment as well as resources to combat these challenges.

Long-Term Monitoring of Teplizumab in T1D

Steve Edelman, MD;Linda A. DiMeglio, MD;Egils K. Bogdanovics, MD;Justin M. Gregory, MD, MSC;Schafer Boeder, MD

August 23rd 2023

Expert endocrinologists discuss implementing long-term monitoring of patients being treated with teplizumab for type 1 diabetes and review the PROTECT study for patients who are newly diagnosed with T1D.

Efficacy of Teplizumab in Clinical Trials

Steve Edelman, MD;Linda A. DiMeglio, MD;Egils K. Bogdanovics, MD;Justin M. Gregory, MD, MSC;Schafer Boeder, MD

August 16th 2023

Egils K. Bogdanovics, MD, and the expert panel review the TN10 study data on the efficacy of teplizumab in delaying the progression of T1D, which led to the drug’s approval from the FDA.

Use of Teplizumab in Delaying T1D

Steve Edelman, MD;Linda A. DiMeglio, MD;Egils K. Bogdanovics, MD;Justin M. Gregory, MD, MSC;Schafer Boeder, MD

August 16th 2023

Justin M. Gregory, MD, MSCI, provides an overview of the mechanism of action of teplizumab and its use in delaying T1D.

Interpreting T1D Antibody Test Results

Steve Edelman, MD;Linda A. DiMeglio, MD;Egils K. Bogdanovics, MD;Justin M. Gregory, MD, MSC;Schafer Boeder, MD

August 9th 2023

Egils K. Bogdanovics, MD, and Schafer Boeder, MD, discuss interpreting antibody test results for type 1 diabetes and provide recommendations for retesting for those who have a negative test or have only 1 antibody present.

T1D Screening Options

Steve Edelman, MD;Linda A. DiMeglio, MD;Egils K. Bogdanovics, MD;Justin M. Gregory, MD, MSC;Schafer Boeder, MD

August 9th 2023

Linda A. DiMeglio, MD, reviews screening options for patients with a family history of T1D, highlighting TrialNet.

Clinical Signs Leading to Diagnostic Testing for T1D

Steve Edelman, MD;Linda A. DiMeglio, MD;Egils K. Bogdanovics, MD;Justin M. Gregory, MD, MSC;Schafer Boeder, MD

August 2nd 2023

Expert endocrinologists discuss the clinical symptoms that prompt testing for T1D, as well the diagnostic testing tools that are available in clinical practice.

Identifying Individuals at High Risk for T1D

Steve Edelman, MD;Linda A. DiMeglio, MD;Egils K. Bogdanovics, MD;Justin M. Gregory, MD, MSC;Schafer Boeder, MD

August 2nd 2023

Justin M. Gregory, MD, MSC, reviews the risk factors of T1D, highlighting a family history of T1D and antibody screening.

Early Diagnosis of T1D

Steve Edelman, MD;Linda A. DiMeglio, MD;Egils K. Bogdanovics, MD;Justin M. Gregory, MD, MSC;Schafer Boeder, MD

July 26th 2023

Linda A. DiMeglio, MD, comments on the importance of early diagnosis of T1D, giving patients the advantage of preparing a treatment plan early.

T1D Staging and Classification

Steve Edelman, MD;Linda A. DiMeglio, MD;Egils K. Bogdanovics, MD;Justin M. Gregory, MD, MSC;Schafer Boeder, MD

July 26th 2023

Expert endocrinologists review the importance of staging and classifying T1D, highlighting dysglycemia.